Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer
about
sameAs
Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysisUse of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control studyThe case for developing publicly-accessible datasets for health services research in the Middle East and North Africa (MENA) regionEffect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis.Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer riskMeta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer riskAspirin and urologic cancer risk: an update.Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies.Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO studyLong-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006.Management of prostate cancer. Part 1: chemoprevention.Evaluation of prostatitis in autopsied prostates--is chronic inflammation more associated with benign prostatic hyperplasia or cancer?Non-Steroidal Anti-Inflammatory Drugs, Variation in Inflammatory Genes, and Aggressive Prostate Cancer.Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis.Inflammation and prostate carcinogenesis.Aspirin and NSAID use in association with molecular subtypes of prostate cancer defined by TMPRSS2:ERG fusion status.Simultaneous treatment with statins and aspirin reduces the risk of prostate cancer detection and tumorigenic properties in prostate cancer cell linesNonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study.Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis.Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies.Intake of Non-steroidal Anti-inflammatory Drugs and the Risk of Prostate Cancer: A Meta-Analysis
P2860
Q28166676-FB306C5F-3E52-40AB-B716-31B12759416DQ28476849-32998F9A-016C-46C2-90F7-36C82DA58A0FQ33513734-306D8F0F-8E03-4AD3-8A91-7CA29945AC9BQ33614082-5B53C648-9EBD-4FB8-BB98-52F0521F58CEQ34179634-8220EE0F-BE8B-43B5-BC75-3F5BA60A79FAQ34325928-10DAE68E-447F-4B45-A1A4-E229AE333B3DQ34635300-E29247E4-C931-4A47-9A68-E4046E2EA6EDQ35136401-2C1BB3F3-40A8-4BD7-B8CF-526FBFE7E817Q36075269-4B9F12C8-7866-4DF3-8830-BA9E95ECAE34Q36241844-E1A80EA2-92AB-46C4-B523-07A89F8ABB06Q36407468-81382413-71F3-4CCB-9D0F-6C2D387A93E1Q37141642-38884DCA-7A11-48E1-A378-E1F9FE704096Q37155271-3F8464FA-AFBF-4703-A68F-9F38AFFF9CD7Q37578293-A3E2DBC6-154A-4A40-B73D-4911860257A9Q38031257-0A3E2A09-259E-4BB2-8866-9B8267D5ACE4Q41184528-DAB979A5-46CB-4634-8229-BF9B08339CD5Q42180829-EC818A84-E4CD-4D89-AEFA-1B82EE321275Q42373340-F0C5E462-8E38-4947-B540-53D3687477AEQ43187352-89F5572A-EC3C-46AC-8D1B-06681BB048ECQ53068177-F14F2221-27A9-4C36-874C-CCEFB5645563Q55312563-380FF4E1-2858-480A-87DF-B0CAF7238D9FQ58573444-860748BB-3FDB-45C3-B4B9-A789E5B6F5BF
P2860
Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Dosage, duration and timing of ...... se and risk of prostate cancer
@ast
Dosage, duration and timing of ...... se and risk of prostate cancer
@en
Dosage, duration and timing of ...... se and risk of prostate cancer
@nl
type
label
Dosage, duration and timing of ...... se and risk of prostate cancer
@ast
Dosage, duration and timing of ...... se and risk of prostate cancer
@en
Dosage, duration and timing of ...... se and risk of prostate cancer
@nl
prefLabel
Dosage, duration and timing of ...... se and risk of prostate cancer
@ast
Dosage, duration and timing of ...... se and risk of prostate cancer
@en
Dosage, duration and timing of ...... se and risk of prostate cancer
@nl
P2093
P356
P1476
Dosage, duration and timing of ...... se and risk of prostate cancer
@en
P2093
François Meyer
Isabelle Bairati
Linda Perron
Lynne Moore
P304
P356
10.1002/IJC.11250
P407
P577
2003-09-01T00:00:00Z